Posts Tagged ‘gsk’

Faulty French Fake Boob Boss Freed

In ALL ARTICLES on January 27, 2012 at 11:13 am
An undated police mugshot photo shows Jean-Claude Mas, the founder of the French Poly Implant Prothese (PIP) company, displayed on the ''red notice'' posted by Interpol on its website. REUTERS/InterpolFrench implant boss released, faces bodily harm charge
MARSEILLE, France (Reuters) – Jean-Claude Mas, the Frenchman who sparked a global health scare by selling substandard breast implants, was released from police custody on Friday and faces a charge of causing bodily harm, his lawyer said. | Full Article
China cadmium spill threatens drinking water for millions
January 27, 2012 04:45 AM ET
BEIJING (Reuters) – A cancer-causing cadmium discharge from a mining company has polluted a long stretch of two rivers in southern China, and officials warned some 3.7 million people of Liuzhou in the Guangxi region to avoid drinking water from the river, state media reported on Friday. | Full Article
Rivals see no need to match Roche’s big gene bet
January 27, 2012 09:08 AM ET
DAVOS, Switzerland (Reuters) – Roche Holding AG’s rivals Sanofi SA and Novartis AG see no need to match the Swiss drug maker in buying a gene-decoding business like Illumina Inc and reckon they can do partnerships instead. | Full Article
Bill Gates injects $750 million into troubled AIDS fund
January 26, 2012 03:31 PM ET
DAVOS, Switzerland (Reuters) – Microsoft chairman and philanthropist Bill Gates pledged a further $750 million to the troubled global AIDS fund on Thursday and urged governments to continue their support to save lives. | Full Article
James Murdoch to quit GSK board
January 27, 2012 07:56 AM ET
LONDON (Reuters) – News Corp executive James Murdoch, under pressure from a phone-hacking scandal at the News of the World tabloid, is to quit the board of drug maker GlaxoSmithKline to spend more time on his media roles. | Full Article

French implant boss released, faces bodily harm charge.

Takeover Talk Has Bulls Buying Human Genome – WSJ.com

In BUSINESS OF STEM CELLS on August 25, 2009 at 9:45 pm


Options traders rallied around pharmaceutical company Human Genome Sciences as talk of a possible buyout by GlaxoSmithKline made the rounds.

Traders flocked to bullish options in Human Genome, picking up 59,000 calls that allow them to buy the company’s stock and 19,000 puts that allow them to sell it, according to Track Data.

Traders showed particular interest in September $20 calls and September $25 calls, hoping that a deal for the Maryland-based company does in fact materialize and sometime before September options expire on Sept. 17.

Spokesmen for Human Genome and Glaxo said they don’t comment on market rumors.

As takeover talk made the rounds, the price of bullish options in Human Genome spiked higher. The price of the September $20 calls more than tripled, for example, rising to $1.85 from 60 cents.

At current prices, the call options make money if Human Genome’s stock climbs above $21.85. It closed the session at $19.21, hitting a high of $19.98.

The implied volatility on Human Genome’s options also increased, said Interactive Brokers senior market analyst Andrew Wilkinson. That suggests investors are preparing for the company’s stock to stage bigger swings.

There was also action in Osiris Therapeutics Inc., a stem-cell therapeutic company conducting clinical trials of Prochymal, a treatment for acute graft versus host disease.

Trading jumped to five times normal, with investors picking up 10,000 calls and 11,000 puts, and implied volatility on the options rose considerably higher. That suggests investors are bracing for the stock to become more volatile. Osiris closed the session at $14.15, up 16 cents, or 1.1%.

via Takeover Talk Has Bulls Buying Human Genome – WSJ.com.

%d bloggers like this: